| Literature DB >> 15378438 |
Douglas S Walsh1, Chirapa Eamsila, Theerayuth Sasiprapha, Suebpong Sangkharomya, Pradith Khaewsathien, Panpaka Supakalin, Douglas B Tang, Phongsak Jarasrumgsichol, Chainarong Cherdchu, Michael D Edstein, Karl H Rieckmann, Thomas G Brewer.
Abstract
We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow-up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria (95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis. Copyright 2004 Infectious Diseases Society of AmericaEntities:
Mesh：
Substances：
Year: 2004 PMID： 15378438 DOI： 10.1086/424468
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226